Clinical Trials
37
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (35 trials with phase data)• Click on a phase to view related trials
A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 2000
- Registration Number
- NCT06792994
- Locations
- 🇩🇪
University Hospital Cologne, Cologne, Germany
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 202
- Registration Number
- NCT05197192
- Locations
- 🇩🇪
Helios Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪DRK Kliniken Berlin Köpenick, Berlin, Germany
🇩🇪Ev. Diakoniekrankenhaus, Bremen, Germany
Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 53
- Registration Number
- NCT04883749
- Locations
- 🇦🇹
Medizinische Universität Innsbruck, Innsbruck, Austria
🇦🇹Hanusch Krankenhaus, Wien, Austria
🇩🇪Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
- Conditions
- Chronic Lymphoid Leukemia
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 897
- Registration Number
- NCT04608318
- Locations
- 🇦🇹
LKH-Universtitätsklinikum Graz, Graz, Austria
🇦🇹Landeskrankenhaus - Universitätskliniken Innsbruck, Innsbruck, Austria
🇦🇹Medizinische Universität Wien, Wien, Austria
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
- Conditions
- Chronic Lymphoid Leukemia
- Interventions
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 42
- Registration Number
- NCT04515238
- Locations
- 🇩🇪
Hamatologische/Onkologische Gemeinschaftspraxis, Augsburg, Germany
🇩🇪Onkologische Schwerpunktpraxis, Esslingen, Germany
🇩🇪Evangelische Krankenhaus Hamm, Hamm, Germany
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next